157 related articles for article (PubMed ID: 33610916)
1. Inhibition of mitochondrial complex III induces differentiation in acute myeloid leukemia.
Zhang Y; Luo T; Ding X; Chang Y; Liu C; Zhang Y; Hao S; Yin Q; Jiang B
Biochem Biophys Res Commun; 2021 Apr; 547():162-168. PubMed ID: 33610916
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
Sykes DB; Kfoury YS; Mercier FE; Wawer MJ; Law JM; Haynes MK; Lewis TA; Schajnovitz A; Jain E; Lee D; Meyer H; Pierce KA; Tolliday NJ; Waller A; Ferrara SJ; Eheim AL; Stoeckigt D; Maxcy KL; Cobert JM; Bachand J; Szekely BA; Mukherjee S; Sklar LA; Kotz JD; Clish CB; Sadreyev RI; Clemons PA; Janzer A; Schreiber SL; Scadden DT
Cell; 2016 Sep; 167(1):171-186.e15. PubMed ID: 27641501
[TBL] [Abstract][Full Text] [Related]
3. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.
Christian S; Merz C; Evans L; Gradl S; Seidel H; Friberg A; Eheim A; Lejeune P; Brzezinka K; Zimmermann K; Ferrara S; Meyer H; Lesche R; Stoeckigt D; Bauser M; Haegebarth A; Sykes DB; Scadden DT; Losman JA; Janzer A
Leukemia; 2019 Oct; 33(10):2403-2415. PubMed ID: 30940908
[TBL] [Abstract][Full Text] [Related]
4. A carboxylic acid isostere screen of the DHODH inhibitor Brequinar.
DeRatt LG; Christine Pietsch E; Tanner A; Shaffer P; Jacoby E; Wang W; Kazmi F; Zhang X; Attar RM; Edwards JP; Kuduk SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127589. PubMed ID: 33007394
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM
EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210
[TBL] [Abstract][Full Text] [Related]
6. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia.
Sykes DB
Expert Opin Ther Targets; 2018 Nov; 22(11):893-898. PubMed ID: 30318938
[No Abstract] [Full Text] [Related]
7. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells.
Wu D; Wang W; Chen W; Lian F; Lang L; Huang Y; Xu Y; Zhang N; Chen Y; Liu M; Nussinov R; Cheng F; Lu W; Huang J
Haematologica; 2018 Sep; 103(9):1472-1483. PubMed ID: 29880605
[TBL] [Abstract][Full Text] [Related]
8. Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Kadir MFA; Othman S; Nellore K
Curr Pharm Biotechnol; 2020; 21(15):1654-1665. PubMed ID: 32525770
[TBL] [Abstract][Full Text] [Related]
9. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N
Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213
[TBL] [Abstract][Full Text] [Related]
10. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
He T; Haapa-Paananen S; Kaminskyy VO; Kohonen P; Fey V; Zhivotovsky B; Kallioniemi O; Perälä M
Oncogene; 2014 Jul; 33(27):3538-49. PubMed ID: 24013224
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M
PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894
[TBL] [Abstract][Full Text] [Related]
13. The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion.
Dembitz V; Tomic B; Kodvanj I; Simon JA; Bedalov A; Visnjic D
J Biol Chem; 2019 Oct; 294(42):15257-15270. PubMed ID: 31431503
[TBL] [Abstract][Full Text] [Related]
14. Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-
Sainas S; Giorgis M; Circosta P; Gaidano V; Bonanni D; Pippione AC; Bagnati R; Passoni A; Qiu Y; Cojocaru CF; Canepa B; Bona A; Rolando B; Mishina M; Ramondetti C; Buccinnà B; Piccinini M; Houshmand M; Cignetti A; Giraudo E; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML
J Med Chem; 2021 May; 64(9):5404-5428. PubMed ID: 33844533
[TBL] [Abstract][Full Text] [Related]
15. The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
Gaidano V; Houshmand M; Vitale N; Carrà G; Morotti A; Tenace V; Rapelli S; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Cilloni D; Cignetti A; Saglio G; Circosta P
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670894
[TBL] [Abstract][Full Text] [Related]
16. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O
Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676
[TBL] [Abstract][Full Text] [Related]
17. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H
Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571
[TBL] [Abstract][Full Text] [Related]
18. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.
Zhou J; Yiying Quah J; Ng Y; Chooi JY; Hui-Min Toh S; Lin B; Zea Tan T; Hosoi H; Osato M; Seet Q; Ooi LAG; Lindmark B; McHale M; Chng WJ
Haematologica; 2020 Sep; 105(9):2286-2297. PubMed ID: 33054053
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
20. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]